PF-00885706 + esomeprazole

PF-00885706 + esomeprazole is a combination therapy developed by Pfizer for the treatment of gastroesophageal reflux disease (GERD), specifically targeting patients who exhibit an inadequate response to proton pump inhibitor (PPI) monotherapy. The combination consists of PF-00885706, a small molecule 5-HT4 receptor partial agonist that acts as a prokinetic agent to enhance gastric motility and esophageal clearance, and esomeprazole, a PPI that reduces gastric acid production by inhibiting the H+/K+ ATPase pump. By addressing both acid secretion and gastrointestinal motility, the therapy aims to provide superior symptom relief compared to standard acid-suppression therapy alone. The combination was evaluated in Phase 2 clinical trials, including a randomized, double-blind, multi-center dose-response study.

Other names

PF-00885706 and esomeprazolePF00885706 and esomeprazolePF 00885706 and esomeprazole